Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review.

Majdoleen Al Alawneh Ahmed Awaisu Ousama Rachid

Published in: Clinical pharmacokinetics (2022)

Variable changes and inconsistencies in different rivaroxaban PK parameters were reported in obese subjects. Further well-designed studies are warranted to better characterize the PK and clinical outcomes of rivaroxaban in subjects with obesity.

Keyphrases

venous thromboembolism
weight loss
atrial fibrillation
metabolic syndrome
pulmonary embolism
type diabetes
adipose tissue
insulin resistance
bariatric surgery
obese patients
weight gain
high fat diet induced
skeletal muscle
case control
physical activity